Heart Valve Disease

Minimally invasive catheter-based treatment options, such as TAVR (Transcatheter Aortic Valve Replacement), are offered for patients who are considered too ill to survive open-heart surgery to replace valves affected by severe stenosis.

The TAVR Team at the UA Sarver Heart Center was established in 2012 under the leadership of Dr. Kapil Lotun. Read more.

The University of Arizona Structural Heart Disease Program team at Banner – University Medical Center Tucson reached another milestone in October 2018, completing the first-ever transcatheter aortic valve replacement (TAVR) procedure on a patient with a bicuspid aortic valve utilizing only transesophageal echocardiography (TEE) to guide them. The procedure also was unique in that only a minimum of contrast dye was employed in final diagnoses preparations for the procedure and no CT (computed tomography) scan was used at all.

Lola Cotton’s first mitral valve surgery served her well for at least five years. “That was a long recovery,” recalled Lola, an 81-year-old resident of Saddlebrooke, Ariz. The minimal invasiveness of the TAVR procedure allowed a faster recovery. “I felt good the first day after my surgery, and went home from the hospital on the third day. Five days later I was back in my pottery studio,” said Lola. Read more.

The TAVR Program at the University of Arizona Sarver Heart Center celebrated its second anniversary in 2014. The TAVR procedure is a minimally invasive catheter-based treatment option for patients who are considered too ill to survive open-heart surgery to replace aortic valves affected by severe aortic stenosis. In this condition, the valve does not open properly and blood cannot leave the heart chambers to get out to the rest of the body. Read how patients are celebrating a return to their "normal" lives.

General Information

More patients with heart valve disease may be candidates for the transcatheter aortic valve replacement (TAVR) procedure as an alternative to open-heart surgery, since the Food and Drug Administration (FDA) expanded the patient eligibility criteria. Read more.

Patient received Trans Aortic Valve replacement at age 96.

Catheter Procedure Gives Patients with Aortic Stenosis Lifesaving Valve Replacement Option

Additional Links